Skip to content
Colorectal Cancer Clinical Trials

Baltimore, Maryland

Colorectal cancer clinical trials in Baltimore, MD

39 colorectal cancer studies are recruiting participants at sites in Baltimore as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Baltimore at a glance

  • 39 studies are recruiting at a site in Baltimore.
  • By phase: Phase 1 (7), Phase 1/2 (7), Phase 2 (7), Phase 2/3 (1), Phase 3 (8), Phase 4 (1), No phase (3), Observational (5). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (26), university, hospital or other (12), government (1).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Baltimore

Basic details from each study's public record (the 30 most recently updated of 39). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Greater Baltimore Medical Center ( Site 0068) · University of Maryland ( Site 2016)
    Registry record
    NCT06997497 · updated
  2. Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Solstice Oncology, Inc.
    Registry record
    NCT07808151 · updated
  3. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Johns Hopkins University
    Registry record
    NCT07020221 · updated
  4. Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Dustin Deming
    Study site
    University of Maryland
    Registry record
    NCT06493019 · updated
  5. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  6. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Kaiser Permanente-Woodlawn Medical Center
    Registry record
    NCT05080673 · updated
  7. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Greater Baltimore Medical Center · Kaiser Permanente-Woodlawn Medical Center · MedStar Franklin Square Medical Center/Weinberg Cancer Institute
    Registry record
    NCT05174169 · updated
  8. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    MedStar Franklin Square Medical Center/Weinberg Cancer Institute · Mercy Medical Center · Sinai Hospital of Baltimore
    Registry record
    NCT05334069 · updated
  9. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study sites
    Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT06418204 · updated
  10. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    MedStar Franklin Square Medical Center
    Registry record
    NCT06662786 · updated
  11. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    MedStar Franklin Square Medical Center
    Registry record
    NCT06750094 · updated
  12. Family Communications After Genetic Testing

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Sinai Hospital of Baltimore
    Registry record
    NCT07143487 · updated
  13. A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Saint Agnes Hospital
    Registry record
    NCT07284849 · updated
  14. The Cancer of the Pancreas Screening-5 CAPS5)Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT02000089 · updated
  15. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Johns Hopkins Hospital /ID# 275645
    Registry record
    NCT07023289 · updated
  16. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Greater Baltimore Medical Center
    Registry record
    NCT07222800 · updated
  17. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT05919264 · updated
  18. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #14
    Registry record
    NCT05176483 · updated
  19. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
    Registry record
    NCT06445062 · updated
  20. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Johns Hopkins
    Registry record
    NCT07349537 · updated
  21. Safety of HRX215 in Patients After Minor and Major Liver Resection

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    HepaRegeniX GmbH
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT06638502 · updated
  22. Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT07147231 · updated
  23. A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    NSABP Foundation Inc
    Study site
    University of Maryland Greenbaum
    Registry record
    NCT07058012 · updated
  24. KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Study site
    Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT06411691 · updated
  25. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Seagen, a wholly owned subsidiary of Pfizer
    Study site
    Sidney Kimmel Comprehensive Cancer at Johns Hopkins
    Registry record
    NCT06131840 · updated
  26. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
    Registry record
    NCT06179160 · updated
  27. Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Study site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT07281768 · updated
  28. A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Takeda
    Study site
    Mercy Medical Center
    Registry record
    NCT06562543 · updated
  29. EXoPERT EMERALD Clinical Study

    • Observational
    • Ages 45 and older
    • All sexes
    Sponsor
    EXoPERT
    Study site
    John Hopkins University
    Registry record
    NCT07186296 · updated
  30. Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

    • No phase
    • Ages 21 and older
    • All sexes
    Sponsor
    Exero Medical Ltd.
    Study site
    Johns Hopkins University
    Registry record
    NCT07337590 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Ask about studies near Baltimore

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call